|
1) Blendler CB, Radebaugh LC, Moheler JL. Topical oxybutinin chloride for relaxation of dys-functional bladders. J Urol. 1989; 141: 1350-2
|
|
|
|
2) 井川靖彦, 柿崎秀宏, 後藤百万, 他. 二分脊椎症に伴う下部尿路機能障害の診療ガイドライン. 日泌尿会誌. 2005; 16: 260-9
|
|
|
|
|
|
3) Palmer LS, Franco I, Kogan SJ, et al. Urolithiasis in children following augmentation cystoplasty. J Urol. 1993; 150: 726-9
|
|
|
|
|
|
4) Filmer RB, Spencer JR. Malignancies in bladder augmentations and intestinal conduits. J Urol. 1993; 143: 671-8
|
|
|
|
|
|
5) Elder JS, Snyder HM, Hulbert WC, et al. Perforation of the augmented bladder in patients undergoing clean intermittent catheterization. J Urol. 1988; 140: 1159-62
|
|
|
|
|
|
6) De Badiola FIP, Castro-Diaz D, Hart-Austin C, et al. Influence of preoperative bladder capacity and compliance on the outcome of artificial sphincter implantation in patients with neuro-genic sphincter incompetence. J Urol. 1992; 148: 1493-5
|
|
|
|
|
|
7) Greenfield SP, Fera M. The use of intravesical oxybutynin chloride in children with neurogenic bladder. J Urol. 1991; 146: 532-4
|
|
|
|
|
|
8) Painter KA, Vates TS, Bukowski TP, et al. Long-term intravesical oxybutynin chloride therapy in children with myelodysplasia. J Urol. 1996; 156: 1459-62
|
|
|
|
|
9) Amark P, Bussman G, Eksborg S. Follow-up of long time treatment with intravesical oxybutynin for neurogenic bladder children. Eur Urol. 1998; 34: 148-53
|
|
|
|
|
|
10) Reitz A, Schurch. Intravesical therapy options for neurogenic detrusor overactivity. Spinal Cord. 2004; 42: 267-72
|
|
|
|
|
|
11) Kim Y, Yoshimura N, Masuda H, et al. Anti-muscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder afferent pathways. Urology. 2005; 65: 238-42
|
|
|
|
|
|
12) Abrams P, Andersson KE, Buccafusco JJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148: 565-78
|
|
|
|
|
|
13) Saito M, Tabuchi F, Otsubo K, et al. Treatment of overactive bladder with modified intravesical oxybutynin chloride. Neurourol Urodyn. 2000; 19: 638-8
|
|
|
|
|
|
14) Stasi SMD, Giannantoni A, Navarra P, et al. Intravesical oxybutynin: mode of action assessed by passive diffusion and electromotive administration with pharmacokinetics of oxybutynin and N-Desethyl oxybutynin. J Urol. 2001; 166: 2232-6
|
|
|
|
|
|
15) Weeze DL, Roskamp DA, Leach GE, et al. Intavesical oxybutynin chloride: experience with 42 patients. Urology. 1993; 41: 527-30
|
|
|
|
|
|
16) Kasabian NG, Vlachiotis JD, Lais A, et al. The use of intravesical oxybutynin chloride in patients with detrusor hyperactivity and detrusor hyperreflexia. J Urol. 1994; 151: 944-5
|
|
|
|
|
|
17) Palmer LS, Zebold K, Firlit CF, et al. Com-plications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population. J Urol. 1997; 157: 638-40
|
|
|
|
|
|
18) Lee MW, Greenfield SP. Intractable high-pressure bladder in female infants with spine bifida: Clinical characteristics and use of vesicostomy. Urology. 2005; 65: 568-71
|
|
|
|
|
|
19) Landau EH, Fung LCT, Thorner PS, et al. Histologic studies of intravesical oxybutynin in the rabbit. J Urol. 1995; 153: 2022-4
|
|
|
|
|
|
20) Mizunaga M, Kaneko S, Miyata M, et al. New intravesical oxybutinin hydrochloride used for the treatment of neurogenic bladder dysfunction. Neurourol Urodyn. 1996; 15: 306-7
|
|
|
|
|
|
21) 城谷健二, 木内弘道, 徳永 葉, 他. 塩酸オキシブチニン膀胱内注入療法の膀胱蓄尿機能に与える影響について. 泌尿器外科. 2001; 14: 221-6
|
|
|
|
|
22) 山下恭範, 千葉 薫, 小野尚志, 他. 塩酸オキシブチニン膀胱内注入療法における長期臨床使用成績調査?難治性尿失禁患者のQOLを改善した院内製剤?. 医療薬学. 2004; 30: 83-7
|
|
|
|
|
|
23) Saito M, Watanabe T, Tabuchi F, et al. Uro-dynamic effects and safety of modified intra-vesical oxybutynin chloride in patients with neurogenic detrusor overactivity: 3 years experience. Int J Urol. 2004; 11: 592-6
|
|
|
|
|
|
24) Hayashi A, Saito M, Okada S, et al. Treatment with modified intravesical oxybutinin chloride for neurogenic bladder in children. J Pediatr Urol 2007; 3: 438-42
|
|
|
|
|
|
25) Altaweel W, Jednack R, Bilodeau C, et al. Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele. J Urol. 2006; 175: 1102-5
|
|
|
|
|
|
26) Kaibafzadeh AM, Moosavi S, Tajik P, et al. Intravesical injection of botulinum toxin type A: management of neuropathic bladder and bowel dysfunction in children with myelomeningocele. Urology. 2006; 68: 1091-6
|
|
|
|
|